Skip to main content
Log in

The health economics of bladder cancer

A comprehensive review of the published literature

PharmacoEconomics Aims and scope Submit manuscript

Abstract

The aim of this paper was to conduct a critical systematic review of the available literature on the clinical and economic burden of bladder cancer in developed countries, with a focus on the cost effectiveness of interventions aimed at reducing that burden.

Forty-four economic studies were included in the review. Because of longterm survival and the need for lifelong routine monitoring and treatment, the cost per patient of bladder cancer from diagnosis to death is the highest of all cancers, ranging from $US96 000–187 000 (2001 values) in the US. Overall, bladder cancer is the fifth most expensive cancer in terms of total medical care expenditures, accounting for almost $US3.7 billion (2001 values) in direct costs in the US.

Screening for bladder cancer in the general population is currently not recommended. The economic value of relatively new and less expensive urine assays and molecular urinary tumour markers has not been assessed. However, the literature suggests that screening patients suspected of having bladder cancer and using less invasive diagnostic procedures is cost effective.

Very few cost-effectiveness studies have evaluated intravesical therapies such as bacillus Calmette-Guérin and mitomycin in the management of superficial disease and no robust recommendations can be drawn. Economic analyses suggest that non-surgical treatment strategies for the management of invasive disease aiming at bladder preservation may not be cost effective, because they have not consistently demonstrated survival benefits and do not eliminate the need for subsequent radical cystectomy.

The literature suggests that the current conventional frequent follow-up and monitoring of patients can be cost effectively replaced by less frequent and less invasive monitoring, and should rely more heavily on intravesical chemotherapy to reduce the need for cystoscopies.

Bladder cancer is a fairly common and costly malignancy. Nevertheless, the existing literature only contributes marginally to our knowledge concerning the burden of bladder cancer and the economic value of various interventions. The limited value of the literature in this area may be attributed to (i) being published as abstracts rather than full peer-reviewed evaluations; (ii) employing questionable methodologies; and (iii) being in many cases nearly obsolete, rendering them less relevant to, if not in conflict with, current clinical practice. Consequently, opportunities exist to conduct meaningful economic research in all areas of the management of bladder cancer, including screening, diagnosis, follow-up and treatment, especially with respect to new and innovative pharmaceutical and other technologies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Rseferences

  1. Ferlay J, Bray F, Pisani P, et al.. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5. Lyon: IARC Press, 2001

    Google Scholar 

  2. Miller BA, Kolonel LN, Bernstein L, et al. Racial/ethnic patterns of cancer in the United States 1988–1992. Bethesda (MD): National Cancer Institute; 1996. NIH Pub. No. 96-4104

    Google Scholar 

  3. National Cancer Institute. NCI fact book. Bethesda, (MD): National Institutes of Health; 2000. NIH Pub. No. 01-512

    Google Scholar 

  4. Marcus PM, Hayes RB, Vineis P, et al. Cigarette smoking, Nacetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev 2000; 9 (5): 461–7

    PubMed  CAS  Google Scholar 

  5. Johansson SL, Cohen SM. Epidemiology and etiology of bladder cancer. Semin Surg Oncol 1997; 13 (5): 291–8

    Article  PubMed  CAS  Google Scholar 

  6. Metts MC, Metts JC, Milito SJ, et al. Bladder cancer: a review of diagnosis and management. J Nall Med Assoc 2000; 92 (6): 285–94

    CAS  Google Scholar 

  7. Pow-Sang JM, Seigne JD. Contemporary management of superficial bladder cancer. Cancer Control 2000; 7 (4): 335–9

    PubMed  CAS  Google Scholar 

  8. Dalbagni G, Herr HW. Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer. Urol Clin North Am 2000; 27 (1): 137–46

    Article  PubMed  CAS  Google Scholar 

  9. Lee R, Droller MI. The natural history of bladder cancer. Implications for therapy. Urol Clin North Am 2000; 27 (1): 1–13, vii

    Article  PubMed  CAS  Google Scholar 

  10. Kurth KH, Denis L, Bouffioux C, et al. Factors affecting recurrence and progression in superficial bladder tumours. Fur J Cancer 1995; 31A (11): 1840–6

    CAS  Google Scholar 

  11. Young MJ, Soloway MS. Office evaluation and management of bladder neoplasms. Urol Clin North Am 1998; 25 (4): 603–11

    Article  PubMed  CAS  Google Scholar 

  12. Duque JL, Loughlin KR. An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy. Urol Clin North Am 2000; 27 (1): 125–35, x

    Article  PubMed  CAS  Google Scholar 

  13. Zietman AL, Shipley WU, Kaufman DS. Organ-conserving approaches to muscle-invasive bladder cancer: future altemalives to radical cystectomy. Ann Med 2000; 32 (1): 34–42

    Article  PubMed  CAS  Google Scholar 

  14. Brown ML, Fintor L. The economic burden of cancer. In: Greenwald P, Kramer BS, Weed DL, editors. Cancer prevention and control. New York: Marcel-Dekker, 1995: 69–81

    Google Scholar 

  15. Salkeld G, Morrell S, Webster F, et al. Economic cost of health, effects of occupational exposure to hazardous substances. Australia: National Occupational Health & Safety Commission, 1996

    Google Scholar 

  16. Riley GF, Potosky AL, Lubitz JD, et al. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995; 33 (8): 828–41

    Article  PubMed  CAS  Google Scholar 

  17. Baker S, Kessler LG, Smucker RC. Site-specific treatment costs for cancer: an analysis of the Medicare Continuous History Sample file. In: Scheffler RM, Andrews NC, editors. Cancer care and costs: DRG’s and beyond 1989. Ann Arbor (MI): Health Administration Press Perspectives, 1989

    Google Scholar 

  18. AN Associates Inc. Cost of illness handbook. Washington, DC: United States Environmental Protection Agency, Office of Pollution Prevention and Toxics, 2001

    Google Scholar 

  19. Ruttenberg R, Powers M. Economics of notification and medical screening for high-risk workers. J Occup Med 1986; 28 (8): 757–64

    Article  PubMed  CAS  Google Scholar 

  20. Han M, Schoenberg MP. The use of molecular diagnostics in bladder cancer. Urol Oncol 2000; 5 (3): 87–92

    Article  PubMed  CAS  Google Scholar 

  21. Ellwein LB, Farrow GM, Friedell GH, et al. An assessment of the impact of urine cytology screening using a computer-based model of bladder cancer. Urol Clin North Am 1984; 11 (4): 585–98

    PubMed  CAS  Google Scholar 

  22. Messing EM, Young TB, Hunt VB, et al. Hematuria home screening: repeat testing results. J Urol 1995; 154 (1): 57–61

    Article  PubMed  CAS  Google Scholar 

  23. Brausi M, Ferretti S. Screening for asymptomatic microscopic hematuria (MA) in a health population: results of a study of 2065 individuals [abstract]. J Urol 2000; 163 (4 Suppl.): 3

    Google Scholar 

  24. Ellison LM, Ellsworth PI, Birkmeyer JD. Cost-effectiveness of screening for bladder cancer after radiation therapy for prostate cancer [abstract]. J Urol 2000; 163 (4 Suppl.): 3

    Google Scholar 

  25. Burchardt M, Burchardt T, Shabsigh A, et al. Current concepts in biomarker technology for bladder cancers. Clin Chem 2000; 46 (5): 595–605

    PubMed  CAS  Google Scholar 

  26. Cummings KB, Barone JG, Ward WS. Diagnosis and staging of bladder cancer. Urol Clin North Am 1992; 19 (3): 455–65

    PubMed  CAS  Google Scholar 

  27. Corwin HL, Silverstein MD. The diagnosis of neoplasia in patients with asymptomatic microscopic hematuria: a decision analysis. J Urol 1988; 139 (5): 1002–6

    PubMed  CAS  Google Scholar 

  28. Zippe C, Pandrangi L, Agarwal A. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol 1999; 161 (1): 62–5

    Article  PubMed  CAS  Google Scholar 

  29. Zippe C, Pandrangi L, Potts JM, et al. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer. Anticancer Res 1999; 19 (4A): 2621–3

    PubMed  CAS  Google Scholar 

  30. Hansen MV, Zdanowski A. The agreement among urological experts on the diagnostic management of patients with common mological problems. Br J Urol 1997; 80 (5): 787–92

    Article  PubMed  CAS  Google Scholar 

  31. Hunt MT, Woodhouse CR. Cost-effectiveness of investigations for invasive bladder cancer. J R Soc Med 1987; 80 (3): 143–4

    PubMed  CAS  Google Scholar 

  32. Lindner A, deKernion JB. Cost-effective analysis of pre-cystectomy radioisotope scans. J Urol 1982; 128 (6: 1181–2

    PubMed  CAS  Google Scholar 

  33. Kiemeney LA, Wiges JA, Heijbroek RP, et al. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993; 150 (1): 60–4

    PubMed  CAS  Google Scholar 

  34. Raitanen MP, Tammela TL. Impact of tumour grade, stage, number and size, smoking habits and sex on the recurrence rate and disease-free interval in patients with transitional cell carcinoma of the bladder. Ann Chir Gynaecol 1995; 84 (1): 37–41

    PubMed  CAS  Google Scholar 

  35. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000; 164 (3 Pt 1): 680–4

    Article  PubMed  CAS  Google Scholar 

  36. Zlotta AR, Schulman CC. Biological markers in superficial bladder tumors and their prognostic significance. Urol Clin North Am 2000; 27 (1): 179–xii

    Article  PubMed  CAS  Google Scholar 

  37. Kurth KH, Bouffioux C, Sylvester R, et al. Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group. Fur Urol 2000; 37 Suppl. 3: 1–9

    CAS  Google Scholar 

  38. Smith Jr JA, Labasky RF, Cockett AT, et al. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, TI and TIS): The American Urological Association. J Urol 1999; 162 (5): 1697-701

    Article  PubMed  Google Scholar 

  39. Losa A, Hurle R, Lembo A. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol 2000; 163 (1): 68–71

    Article  PubMed  CAS  Google Scholar 

  40. Birch BR, Anson KM, Miller RA. Sedoanalgesia in urology: a safe, cost-effective alternative to general anaesthesia: a review of 1020 cases. Br J Urol 1990; 66 (4): 342–50

    Article  PubMed  CAS  Google Scholar 

  41. Holmang S, Aldenborg F, Hedelin H. Multiple bladder biopsies under intravesical lignocaine anaesthesia. Br J Urol 1994; 73 (2): 160–3

    Article  PubMed  CAS  Google Scholar 

  42. Hedelin H, Holmang S, Wiman L. Outpatient treatment of bladder cancer: lower cost and satisfied patients. Nord Med 1997; 112 (2): 48–51

    PubMed  CAS  Google Scholar 

  43. Jewett MA, Valiquette L, Sampson HA, et al. Electromotive drug administration of lidocaine as an alternative anesthesia for transurethral surgery. J Urol 1999; 161 (2): 482–5

    Article  PubMed  CAS  Google Scholar 

  44. Shanberg AM, Marinelli D, Tansey LA, et al. Cost analysis of neodymium-YAG laser versus transurethral resection treatment of superficial bladder carcinoma. Int Surg 1993; 78 (4): 350–1

    PubMed  CAS  Google Scholar 

  45. Tellez Martinez-Fornes M, Maganto PE, Vallejo III, et al. Treatment of recurrent bladder surface tumors with laser Nd: Yag: a single-year experience. Actas Urol Esp 1993; 17 (1): 35–9

    Google Scholar 

  46. Smith PH. The costs of intravesical chemotherapy. Prog Clin Biol Res 1985; 185B: 39–44

    PubMed  CAS  Google Scholar 

  47. Baselli EC, Greenberg RE. Intravesical therapy for superficial bladder cancer. Oncology (Huntingt) 2000; 14 (5): 719–29

    CAS  Google Scholar 

  48. Carroll PR, Williams RD, Kim MJ, et al. Mitomycin C reused: an in vitro cost-effectiveness study. J Urol 1984; 132 (3): 583–6

    PubMed  CAS  Google Scholar 

  49. Kilbridge KL, Kantoff PW, Loughlin KR, et al. Is bacillus calmette-guerin (BCG) immunotherapy cost-effective in recurrent high grade transitional cell cancer (TCC)? [abstract]. J Urol 1997; 157 (4 Suppl.): 214

    Google Scholar 

  50. Marchetti A, Wang L, Magar R, et al. Management of patients with bacilli calmette-guerin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin. Clin Ther 2000; 22 (4): 422–38

    Article  PubMed  CAS  Google Scholar 

  51. Rivera I, Wajsman Z. Bladder-sparing treatment of invasive bladder cancer. Cancer Control 2000; 7 (4): 340–6

    PubMed  CAS  Google Scholar 

  52. Sternberg CN. Neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer. Semin Oncol 1996; 23 (5): 621–32

    PubMed  CAS  Google Scholar 

  53. Martinez-Pineiro JA, Martinez-Pineiro L. The role of neoadjuvant chemotherapy for invasive bladder cancer. Br J Urol 1998; 82 (1): 33–42

    Article  PubMed  CAS  Google Scholar 

  54. von der Maase MIL, Hansen SW, Liepa A, et al. Health care resources use for patients with advanced bladder cancer treated with gemcitabine plus cisplatin (GC) versus MVAC in phase III trial [abstract]. Ann Oncol 2000; 11 (4 Suppl.): 74

    Google Scholar 

  55. von der Maase MIL, Hansen SW, Roberts IT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18 (17): 3068–77

    PubMed  Google Scholar 

  56. Bredin HC, Prout Jr GR. One-stage radical cystectomy for bladder carcinoma: operative mortality, costibenefit analysis. J Urol 1977; 117 (4): 447–51

    PubMed  CAS  Google Scholar 

  57. Zenni MK, Griebling TL, Kreder KJ, et al. Impact of preoperative comorbidity on complications and costs in patients undergoing radical cystectomy and orthotopic urinary diversions [abstract]. J Urol 1998; 159 (5 Suppl.): 53

    Google Scholar 

  58. Klein FA, Whitmore Jr WF. Bladder papilloma: therapeutic and cost effect of outpatient department management. Urology 1981; 18 (3): 247–9

    Article  PubMed  CAS  Google Scholar 

  59. Knoblauch NO, Ronning H, Knudsen P, et al. Routine use of ultrasound and flexible cystoscopy in the control of benign bladder tumours. Int Urol Nephrol 1994; 26 (4): 431–6

    Article  PubMed  CAS  Google Scholar 

  60. Hall RR, Parmar MK, Richards AB, et al. Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy. BMJ 1994; 308 (6923): 257–60

    Article  PubMed  CAS  Google Scholar 

  61. Kilbridge KL, Kuntz KM, Kagan AR, et al. The cost-effectiveness (CE) of frequent follow-up (F/U) in superficial transitional cell cancer (TCC) of the bladder [abstract]. Am Soc Clin Oncol 1996; 15: 326

    Google Scholar 

  62. Nam RK, Redelmeier DA, Spiess PE, et al. Comparison of molecular and conventional strategies for follow-up of superficial bladder cancer using decision analysis. J Urol 2000; 163 (3): 752–7

    Google Scholar 

  63. Lachaine J, Valiquette L, Crott R. Economic evaluation of NMP22 in the management of bladder cancer. Can J Urol 2000; 7 (2): 974–80

    PubMed  CAS  Google Scholar 

  64. Lotan Y, Roehrborn CG. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach. J Urol 2002; 167 (1): 75–9

    Article  PubMed  Google Scholar 

  65. The use of the bladder-tumour associated analyte test to determine the type of cystoscopy in the follow-up of patients with bladder cancer. The United Kingdom and Eire Bladder Tumour Antigen Study Group. Br J Urol 1997; 79 (3): 362-6

    Google Scholar 

  66. Neymark N, Torts K. Economics of urinary tract cancers: state of the art. Eur Urol 1997; 31 Suppl. 1: 72–81

    PubMed  Google Scholar 

Download references

Acknowledgements

This research was sponsored in part by Pharmacia. The authors do not have any conflicts of interests relevant to the contents of this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Marc F. Botteman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Botteman, M.F., Pashos, C.L., Redaelli, A. et al. The health economics of bladder cancer. Pharmacoeconomic 21, 1315–1330 (2003). https://doi.org/10.1007/BF03262330

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03262330

Keywords

Navigation